Race Oncology Limited announced the appointment of Dr Peter Smith as a Non-Executive Director, replacing Daniel Sharp who has advised his resignation to concentrate on other personal and professional interests. Dr Peter (Pete) Smith has over 30 years of experience in a broad range of activities in the healthcare industry with a strong focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies.

He is currently CEO of private company, Myrio Therapeutics (formerly Affinity Bio.) Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD (later acquired by CSL.) Prior to moving to Australia, Pete co-founded and was CFO of Onyvax Ltd, a cancer immune-therapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC and was involved in numerous transactions including IPOs, fundraisings and M&A. His undergraduate degree and PhD are from the University of Cambridge, the latter in the field of cell-signalling. He is currently also a Director of private companies, Hula Therapeutics and Amala Therapeutics.